TABLE 2.
Characteristic | n | Mean ± SD | Median | Range |
---|---|---|---|---|
Tumor site | ||||
Soft tissue or lymph node | 113 (22) | |||
Lung | 14 (3) | |||
Axial skeleton or spine | 225 (45) | |||
Long bone or pelvis | 153 (30) | |||
| ||||
PET measures (LBM-adjusted) | ||||
18F-fluoroestradiol mean SUVLBM | 1.9 ± 1.5 | 1.5 | 0.0–10.2 | |
18F-fluoroestradiol maximum SUVLBM | 2.9 ± 1.9 | 2.3 | 0.2–13.0 | |
18F-FDG maximum SUVLBM (n = 492) | 3.2 ± 2.2 | 2.5 | 0.8–16.5 | |
18F-fluoroestradiol maximum/18F-FDG maximum ratio (n = 492) | 1.1 ± 0.9 | 0.9 | 0.1–5.6 | |
| ||||
PET measures (total mass-adjusted) | ||||
18F-fluoroestradiol mean SUV | 3.0 ± 2.4 | 2.3 | 0.0–14.7 | |
18F-fluoroestradiol maximum SUV | 4.5 ± 3.1 | 3.6 | 0.3–18.7 | |
18F-FDG maximum SUV (n = 492) | 5.0 ± 3.4 | 3.8 | 1.2–25.0 |
n = 505 lesions in 91 patients. Data in parentheses are percentages.